Why the study?
Dilated cardiomyopathy lacks specific treatments and has poor prognosis, prompting review of OPA1 as an essential mediator and molecular regulator linking p53 to apoptosis, mitochondrial dynamics imbalance, and cristae structure changes.
Answers are grounded in this paper and cite their sources.
This review highlights OPA1 as a critical molecular mediator in the pathogenesis of dilated cardiomyopathy, linking P53 activation to mitochondrial dysfunction and apoptosis.
Dilated cardiomyopathy (DCM) is a disease with no specific treatment, poor prognosis and high mortality. During DCM development, there is apoptosis, mitochondrial dynamics imbalance and changes in cristae structure. Optic atrophy 1 (OPA1) appears at high frequency in these three aspects. DCM LMNA (LaminA/C) gene mutation can activate TP53, and the study of P53 shows that P53 affects OPA1 through Bak/Bax and OMA1 (a metalloprotease). OPA1 can be considered the missing link between DCMp53 and DCM apoptosis, mitochondrial dynamics imbalance and changes in cristae structure. OPA1 regulates apoptosis by regulating the release of cytochrome c from the mitochondrial matrix through CJs (crisp linkages, located in the inner mitochondrial membrane) and unbalances mitochondrial fusion and fission by affecting mitochondrial inner membrane (IM) fusion. OPA1 is also associated with the formation and maintenance of mitochondrial cristae. OPA1 is not the root cause of DCM, but it is an essential mediator in P53 mediating the occurrence and development of DCM, so OPA1 also becomes a molecular regulator of DCM. This review discusses the implication of OPA1 for DCM from three aspects: apoptosis, mitochondrial dynamics and ridge structure.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: